Unfractionated heparin inhibits live wild type SARS‐CoV‐2 cell infectivity at therapeutically relevant concentrations-Reference-Cited by-同舟云学术

Unfractionated heparin inhibits live wild type SARS‐CoV‐2 cell infectivity at therapeutically relevant concentrations

Published:2020-12-14 Issue:3 Volume:178 Page:626-635
ISSN:0007-1188
Container-title:British Journal of Pharmacology
language:en
Short-container-title:Br J Pharmacol

Author:

Tree Julia A.¹,Turnbull Jeremy E.²³,Buttigieg Karen R.¹,Elmore Michael J.¹,Coombes Naomi¹,Hogwood John⁴,Mycroft‐West Courtney J.⁵,Lima Marcelo A.⁵,Skidmore Mark A.⁵,Karlsson Richard³,Chen Yen‐Hsi³,Yang Zhang³,Spalluto Cosma Mirella⁶,Staples Karl J.⁶,Yates Edwin A.²,Gray Elaine⁴⁷,Singh Dave⁸,Wilkinson Tom⁶,Page Clive P.⁷,Carroll Miles W.¹⁹

Affiliation:

1. National Infection Service, Public Health England, Porton Down Salisbury UK

2. Department of Biochemistry and Systems Biology, Institute of Systems, Molecular & Integrative Biology University of Liverpool Liverpool UK

3. Copenhagen Center for Glycomics, Department of Cellular & Molecular Medicine University of Copenhagen Copenhagen Denmark

4. Haemostasis Section, Biotherapeutics National Institute for Biological Standards and Control (NIBSC) Potters Bar UK

5. Molecular & Structural Biosciences, School of Life Sciences Keele University Newcastle‐Under‐Lyme UK

6. Department of Respiratory Medicine University of Southampton Southampton UK

7. Sackler Institute of Pulmonary Pharmacology King's College London London UK

8. Medicines Evaluation Unit University of Manchester, Manchester University Hospital NHS Foundation Trust Manchester UK

9. Nuffield Department of Medicine, Wellcome Trust Centre for Human Genetics Oxford University Oxford UK

Funder

Public Health England

University of Liverpool

Publisher

Wiley

Subject

Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bph.15304

Reference36 articles.

1. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview

2. The association between treatment with heparin and survival in patients with Covid-19

3. SARS‐CoV‐2 infection and transmission depends on heparan sulfates and is blocked by low molecular weight heparins;Bermejo‐Jambrina M.;BioRxiv,2020

4. Isolation and rapid sharing of the 2019 novel coronavirus ( SARS ‐CoV‐2) from the first patient diagnosed with COVID ‐19 in Australia

5. Non-Anticoagulant Heparins as Heparanase Inhibitors

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Time in Therapeutic Range of Unfractionated Heparin-Based Therapy in Critically Ill Patients with COVID-19 Pneumonia;Therapeutics and Clinical Risk Management;2024-09

2. Nebulized enriched heparin improves respiratory parameters in patients with COVID-19: a phase I/II randomized and triple-blind clinical trial;Scientific Reports;2024-08-27

3. Taming the storm: potential anti-inflammatory compounds targeting SARS-CoV-2 MPro;Inflammopharmacology;2024-07-24

4. Antiviral Activities of Heparan Sulfate Mimetic RAFT Polymers Against Mosquito-borne Viruses;ACS Applied Bio Materials;2024-05-03

5. Polysaccharides and Lectins: A Natural Complementary Approach against the SARS-CoV-2 Pandemic;Microbiology Research;2024-04-09